All Stories

After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech

After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics, another struggling biotech.

Feb 9, 2025 - 21:44
 0
After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech
After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics, another struggling biotech.
Read More

Tags:

Previous Article

Illumina posts mixed earnings report while dealing with China tariff fallout

Next Article

Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win

Related Posts

Illumina posts mixed earnings report while dealing with China tariff fallout

Illumina posts mixed earnings report while dealing with...

Feb 9, 2025  0

GSK plans to move vaccine R&D center from Rockville, Md. to the Boston area

GSK plans to move vaccine R&D center from Rockville, Md...

Feb 12, 2025  0

Volta Medical's afib AI shows gains in cardiac ablation study

Volta Medical's afib AI shows gains in cardiac ablation...

Feb 17, 2025  0